Results from an early safety study of Moderna Inc's coronavirus vaccine candidate in older adults showed that it produced virus-neutralising antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers said on Tuesday.

The study, published in the New England Journal of Medicine, offers a more complete picture of the vaccine's safety in older adults, a group at increased risk of severe complications from Covid-19...